Redeye comments on the disappointing news that IRLAB’s drug candidate Pirepemat did not meet its pri...
Cardeon, som investerar i life science-bolag i tidigt skede, har flera attraktiva innehav som gjort ...
Redeye cuts its forecasts and Base Case following a Q4 with negative ARR growth yet improved EBITDA-...
42% decrease of fall rate with pirepemat... ...but no stat.
Substansvärdet sjönk till 4,41 kr vid utgången av 2024 och Fastator avslutade framgångsrikt de skrif...
Redeye is positive about the multiple ascending dose data being in line with previous single ascendi...
Suominen claims it was able to resolve the operational issues it faced during Q3, but this was not y...
Analysguiden inleder bevakning av gruvbolaget Grangex.
Suominen Q4 comparable EBITDA of EUR 4.2m fell 40% short of Vara Research consensus expectation of E...
EMB Mission Bound AB, före detta Embark Group, (”EMB” eller ”Bolaget”) meddelade den 4 mars år 2025 ...
Redeye sees a soft Q4 report from BrightBid. While costs decrease and EBITDA-CAPEX increase, negativ...
Djupgående diskussioner med intressenter Sedan det positiva studieresultatet offentliggjordes i nove...
Redeye updates its estimates and fair value range following Dala Energi’s Q4 report last week.
Redeye provides an update on Scandinavian ChemoTech following the Q4 2024 report.
Hifab Group AB (”Hifab”, ”Koncernen” eller ”Bolaget”) meddelade den 4 mars år 2025 att Bolaget har t...
Redeye comments on BioInvent's fourth-quarter report 2024.
Med en välfylld kassa efter en framgångsrik emission, flera pågående dialoger med möjliga samarbetsp...
7% premium to last 3-month average, slightly below last close Equates to 2.
Redeye returns with a more in-depth take on the Q3 results.
Redeye updates on Northbaze Group following its Q4 results, which were weaker than expected in terms...
